Streetbeat News

Earnings

LRCX

Lam Research (NASDAQ:LRCX) has seen unusual options activity, with a split sentiment among investors: 50% bullish and 50% bearish. The activity includes 2 puts and 8 calls, with a significant move suggesting a price target between $920.0 and $1045.0. The trading volume and open interest indicate heightened interest in LRCX options. Analyst opinions on LRCX are mixed, with an average target price of $976.67, but Cantor Fitzgerald downgraded it to Neutral with a $900 target, while UBS maintains a Buy rating with a $1130 target. The stock's current price is $966.74, with an upcoming earnings announcement in 20 days.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 3:01 pm

ADI

An industry comparison of Analog Devices (ADI) against its competitors in the Semiconductors & Semiconductor Equipment sector reveals potential undervaluation based on PE, PB, and PS ratios. However, ADI's lower ROE, EBITDA, gross profit, and revenue growth suggest weaker financial performance. The analysis includes financial metrics and market positions of ADI and its major competitors, highlighting ADI's significant market share in converter chips and its financial positioning relative to industry averages.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 3:00 pm

ADBE

The analysis compares Adobe (ADBE) with its competitors in the Software industry, focusing on financial metrics like P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. Adobe shows potential undervaluation based on its P/E ratio, overvaluation in terms of P/B, and undervaluation regarding P/S. Its ROE is below the industry average, but it has higher EBITDA and gross profit, indicating strong profitability. However, Adobe's revenue growth is significantly lower than the industry average.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 3:00 pm

AVTX

REX

REX American Resources Corporation (NYSE:REX) reported quarterly GAAP earnings of $1.16 per share, surpassing estimates of 68 cents, causing its shares to jump 23.2% to $54.15. Other stocks also saw significant gains, including Avalo Therapeutics, Inc. (NASDAQ:AVTX) with a 430% increase after acquiring a Phase 2-ready anti-IL-1β mAb and announcing a private placement financing of up to $185 million. Various companies across different sectors recorded gains in their stock prices following positive earnings reports, acquisitions, and analyst upgrades.

Portfolio Pulse from Avi Kapoor

March 28, 2024 | 3:00 pm

ABEV

A comprehensive analysis comparing Ambev (NYSE:ABEV) with its competitors in the Beverages industry reveals mixed performance indicators. Ambev's low PE ratio suggests potential undervaluation, while its high PB and PS ratios indicate possible overvaluation. The company demonstrates high ROE but faces challenges with lower EBITDA, gross profit, and negative revenue growth compared to industry peers. This analysis highlights Ambev's operational efficiency and growth potential within the industry.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 3:00 pm

SMMT

Akeso Inc. reported a significant profit of 1.94 billion yuan for 2023, driven by a surge in licensing income and product sales. The company's partnership with Summit Therapeutics contributed significantly to its revenue. Akeso's rights issue aims to raise funds for further R&D, leveraging its positive earnings. The company's flagship product, cadonilimab, and its next anticipated drug, ivonescimab, are key to its future growth. Despite a high P/E ratio, analysts are optimistic about Akeso's earnings outlook.

Portfolio Pulse from The Bamboo Works

March 28, 2024 | 2:58 pm

DNA

Ginko Bioworks Holdings' stock price increased following the announcement of a contract award worth up to $6 million from the Defense Advanced Research Projects Agency (DARPA).

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 2:57 pm

SY

So-Young International Inc. (NASDAQ:SY) reported a pivot to profitability and a focus on high-end services, leading to a 19% revenue increase last year. The launch of So-Young Prime and a strategic shift away from smaller clinics contributed to this success. Despite challenges from COVID-19 and regulatory crackdowns, the company's shift towards premium services and direct provision of cosmetic products and services shows promise. A $25 million share repurchase and a special cash dividend were announced, although a modest revenue growth forecast tempers optimism.

Portfolio Pulse from The Bamboo Works

March 28, 2024 | 2:55 pm

PUBM

A correction has been issued stating that PubMatic (PUBM) did not report its earnings today as previously announced.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 2:46 pm

PUBM

PubMatic (NASDAQ:PUBM) reported Q4 earnings of $0.34 per share, surpassing the consensus estimate of $0.30 by 13.33%. Quarterly sales were $56.24M, exceeding estimates of $47.54M by 18.30%.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 2:45 pm